RPGRIP1L Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-88181
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Format
BSA Free
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the N-terminal region of Human RPGRIP1L. Peptide sequence: HARKQEDKIKRMATKLIRLVNDKKRYERVGGGPKRLGRDVEMEEMIEQLQ The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Description
Novus Biologicals Rabbit RPGRIP1L Antibody - BSA Free (NBP2-88181) is a polyclonal antibody validated for use in WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
Scientific Data Images for RPGRIP1L Antibody - BSA Free
Western Blot: RPGRIP1L Antibody [NBP2-88181]
Western Blot: RPGRIP1L Antibody [NBP2-88181] - Host: Rabbit. Target Name: FTM. Sample Type: 293T Whole Cell lysates. Antibody Dilution: 1ug/mlApplications for RPGRIP1L Antibody - BSA Free
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: RPGRIP1L
Alternate Names
CORS3, FTMDKFZp686C0668, JBTS7fantom homolog, KIAA1005RPGRIP1-like protein, MKS5nephrocystin 8, NPHP8, protein fantom, RPGR-interacting protein 1-like protein, RPGRIP1-like
Gene Symbol
RPGRIP1L
Additional RPGRIP1L Products
Product Documents for RPGRIP1L Antibody - BSA Free
Product Specific Notices for RPGRIP1L Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...